ECE2023 Poster Presentations Endocrine-related Cancer (62 abstracts)
Clinical implications of splicing machinery alteration in Pheochromocytomas and Paragangliomas
María Trinidad Moreno Montilla 1,2,3 , Víctor García Vioque 1,2,3 , Ricardo Blázquez Encinas Rey 1,2,3 , Angel Mario Martinez Montes 4 , Emilia Alors-Pérez 1,2,3 , Federica Mangili 1,2,3,5 , Sergio Pedraza-Arevalo 1,2,3 , Mercedes Robledo 4,6 , Justo P. Castaño 1,2,3,7 & Alejandro Ibañez Costa 1,2,3
1Maimonides Biomedical Research Institute of Cordoba, Cordoba, Spain; 2Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain; 3Reina Sofia University Hospital, Cordoba, Spain; 4Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 5Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 6Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERer), Madrid, Spain; 7CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain
Pheochromocytomas and paragangliomas (PPGL) are infrequent neuroendocrine neoplasms, which develop metastases or aggressive behaviour in 25 % patients. They can be classified into three clusters according to their molecular features; nevertheless, these differences may not stratify patients according to their prognosis. The dysregulation of the splicing process has emerged as a novel feature shared by most cancers, which is associated with an aggressive phenotype in several tumours, including NETs, but it has not been explored in PPGL. The purpose of this study was to determine the splicing machinery profile in PPGL, its relationship with clinical/molecular features, and to investigate the functional role of splicing inhibitors in vitro. We investigated the expression of 310 splicing-related genes in a dataset of 196 PPGL and analysed their relationship with clinical features of patients and tumor phenotypes, which was validated using the TCGA dataset. SK-N-AS (WT and SDHB knock-down), and PC12 cell lines were used to perform in vitro assays testing the effects of the SF3B1 inhibitor Pladienolide B. Pheochromocytomas and paragangliomas show clearly distinct profiles of splicing machinery components. Interestingly, clear differences were observed among the molecular clusters. Furthermore, the expression levels of certain splicing-related genes were associated to metastasis, aggressiveness, and low survival. The in vitro blockade of the splicing process reduced functional parameters of aggressiveness as proliferation, colony formation, migration, and sphere formation. Finally, our findings revealed that the splicing machinery is severely altered in PPGL, which may be associated with key clinical features, and its modulation may improve tumour aggressiveness.
Keywords: pheochromocytoma, paraganglioma, splicing dysregulation, splicing machinery, pladienolide B.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more